- Home
- ALT
ALT
Altimmune Inc.
as 11-21-2024 11:30am EST
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 457.0M | IPO Year: | N/A |
| Target Price: | $20.00 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.48 - $14.84 | Next Earning Date: | 11-12-2024 |
| Revenue: | $52,000 | Revenue Growth: | -81.36% |
| Revenue Growth (this year): | -98.58% | Revenue Growth (next year): | N/A |
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Simply Wall St.
7 days ago
Altimmune Third Quarter 2024 Earnings: Beats Expectations
GlobeNewswire
9 days ago
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
10 days ago
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
10 days ago
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
GlobeNewswire
14 days ago
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
GlobeNewswire
15 days ago
Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewswire
17 days ago
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Compare ALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.